Table 3.
Stimulated T cell activation subsets prerituximab and 6 months postrituximab in FSGS rituximab responders and nonresponders compared with patients with minimal change nephrotic syndrome in relapse and healthy controls
| Immunologic Subsets | Subset, % | |||||
|---|---|---|---|---|---|---|
| FSGS Rituximab | MCNS in Relapse, n=22 | Control, n=30 | ||||
| FSGS Rituximab Responders, n=12 | FSGS Rituximab Nonresponders, n=10 | |||||
| Prerituximab | 6 mo Postrituximab | Prerituximab | 6 mo Postrituximab | |||
| T cell activation | ||||||
| CD69+CD3+ | 89.1±8.6 | 92.2±7.0 | 93.3±3.3 | 90.0±10.7 | 89.1±7.6 | 91.4±9.4 |
| CD154+CD4+CD3+ | 54.9±28.1a | 74.8±17.2b | 78.9±16.4 | 78.4±13.3 | 64.2±23.5 | 75.7±13.2 |
| IFN-γ+CD3+ | 0.6±0.8a,c,d | 7.1±7.7b | 7.5±6.1 | 7.2±6.7 | 7.8±11.2 | 12.8±11.2 |
| IL-2+CD3+ | 0.2±0.5a,c | 7.9±10.9b | 4.0±4.7 | 3.4±4.8 | 4.3±7.4 | 6.9±8.4 |
Results are expressed as mean±SD. MCNS, minimal change nephrotic syndrome. Comparison between groups was performed using the Mann–Whitney U Test with Bonferroni correction for multiple subset comparison.
a
P<0.05: comparing FSGS rituximab responders and healthy controls.
b
P<0.05: paired analysis comparing prerituximab and 6 months postrituximab therapy (Wilcoxon signed rank test).
c
P<0.05: comparing FSGS rituximab responders and FSGS rituximab nonresponders.
d
P<0.05: comparing FSGS rituximab responders and MCNS in relapse.